Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-08
2008-04-08
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S378000, C514S254100, C514S307000, C514S316000, C548S245000, C548S246000, C548S247000, C544S137000, C544S367000, C546S272100, C546S146000, C546S189000, C546S209000
Reexamination Certificate
active
07354919
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula:where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
REFERENCES:
patent: 5470862 (1995-11-01), Lin et al.
patent: 5498720 (1996-03-01), Lee
patent: 2005/0101650 (2005-05-01), Aronov et al.
patent: 44 38 824 (1995-04-01), None
patent: 0827130 (1996-01-01), None
patent: 2000 086657 (2000-03-01), None
patent: WO 98/15542 (1998-04-01), None
patent: WO 98/35944 (1998-08-01), None
patent: WO 99/61440 (1999-12-01), None
patent: WO 01/56557 (2001-08-01), None
patent: WO 01/57022 (2001-08-01), None
Obach R.S., Drug-drug interactions; An important negative attribute in drugs, Drugs of Today, 39(5), 301-38, (2003).
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL;http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Huff, Journal of Medicinal Chemistry, vol. 34, No. 8, pp. 2305-2314, (1991).
Chang, et al., “Role of cAMP-Dependent Pathway in Eosinophil Apoptosis and Survival,” Cellular Immunology; 203;29-38 (2000).
Frey and Mulder, “TGFβ regulation of mitogen-activated protein kinases in human breast cancer cells,” Cancer Letters, 117:41-50 (1997).
Fukunaga and Miyamoto, “Role of MAP Kinase in Neurons,” Molecular Neurobiology, 16(1):79-95 (1998).
Hoshino, et al., “Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene, 18:813-822 (1999).
Illenberger, et al., “The Endogenous and Cell Cycle-dependent Phosphorylation of tau Protein in Living Cells: Implications for Alzheimer's Disease,” Molecular Biology of the Cell, 9:1495-1512 (Jun. 1998).
Kodama, et al., “Significance of ERK cascade compared with JAK/STAT and P13-K pathway in gp130-mediated cardiac hypertrophy,” Am. J. Physiol Heart Circ Physiol, 279:H1635-H1644, (2000).
Kortylewski, et al., “Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells,” Biochem J., 357:297-303, (2001).
Namura, et al., “Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia,” PNAS, 98(20);11569-11574 (Sep. 25, 2001).
Putz, et al., “Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines,” Cancer Research, 59:227-233 (Jan. 1, 1999).
Raghunandan and Ingram, “Hyperphosphorylation of the Cytoskeletal Protein Tau by the MAP-Kinase PK40erk2: Regulation by Prior Phosphorylation with cAMP-Dependent Protein Kinase A,” Biochemical and Biophysical Research Communications, 215(3);1056-1066, (Oct. 24, 1995).
Slevin, et al., “Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” NeuroReport, 11(12);2759-2764 (Aug. 21, 2000).
Holland et al, “Heterocyclic tetrazoles, a new class of lipolysis inhibitors”, J. Med. Chem., 10(2): 149-154, 1967.
Almerico et al, “Polycondensed nitrogen heterocycles. Part 17. Isoxazolo-4,3-pyrazolo-3,4-f-1,2,3-triazepine. A new ring system”, J. Heterocyclic Chem., 24(5): 1309-1311, 1987.
Tanaka et al, “Synthesis and properties of H-1,2,3-triazoles”, Tetrahedron, 29(21): 3271-3285, 1973.
Bang et al, “Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships”, J. Med. Chem., 40(18): 2831-2842, 1997.
Jones et al, “1,3-Dipolar addition reactions with vinylpyrroles”, Heterocycles, 14(2): 185-188, 1980.
Ajello et al, “New syntheses of condensed heterocycles from isoxazole derivatives. III. s-Triazolo[3,4]pyridazines”, J. Het. Chem., 9(4): 1169-1170, 1972.
Aiello et al, “Synthesis and antimicrobial activity of new 3-(1R-3(5)-methyl-4-nitroso-1H-5(3)-pyrazolyl)-5-methylisoxazoles”, Bioorg. Med. Chem., 8(12): 2719-2728, 2000.
Musante et al, Gazz. Chim. Ital., 79, 1949.
Cao Jingrong
Hale Michael R.
Janetka James W.
Maltais Francois
Anderson Rebecca
Pearson Daniel A.
Vertex Pharmaceuticals Incorporated
LandOfFree
Isoxazole compositions useful as inhibitors of ERK does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazole compositions useful as inhibitors of ERK, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazole compositions useful as inhibitors of ERK will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2787832